


Journal Pre-proof

Sweetener influences plasma concentration of flavonoids in humans after an acute intake of a new (poly)phenol-rich beverage

Vicente Agulló, Raúl Domínguez-Perles, Cristina García-Viguera



PII: S0939-4753(20)30493-2

DOI: <https://doi.org/10.1016/j.numecd.2020.11.016>

Reference: NUMECD 2511

To appear in: *Nutrition, Metabolism and Cardiovascular Diseases*

Received Date: 12 August 2020

Revised Date: 22 October 2020

Accepted Date: 16 November 2020

Please cite this article as: Agulló V, Domínguez-Perles R, García-Viguera C, Sweetener influences plasma concentration of flavonoids in humans after an acute intake of a new (poly)phenol-rich beverage, *Nutrition, Metabolism and Cardiovascular Diseases*, <https://doi.org/10.1016/j.numecd.2020.11.016>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier B.V. on behalf of The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University.

NUTRITION, METABOLISM, AND CARDIOVASCULAR DISEASES

Sweetener influences plasma concentration of flavonoids in humans after an acute intake of a new (poly)phenol-rich beverage

GRAPHICAL ABSTRACT




Figure caption: Sweetener influences plasma concentration of flavonoids in humans after an acute intake of a new (poly)phenol-rich beverage

1 *Research article*

2 **Sweetener influences plasma concentration of flavonoids in**
3 **humans after an acute intake of a new (poly)phenol-rich**
4 **beverage**

5 Vicente Agulló, Raúl Domínguez-Perles,* Cristina García-Viguera

6 *Phytochemistry and Healthy Foods Lab. Group of Quality, Safety, and Bioactivity of Plant Foods.*

7 *Department of Food Science and Technology, CEBAS-CSIC, University Campus of Espinardo, Edif. 25,*

8 *E-30100 Murcia, Spain.*

9

10

11

12

13

14 Running title: Influence of sweeteners in the metabolism of flavonoids

15

16

17

18

19

20

21 * Corresponding author: rdperles@cebas.csic.es (Domínguez-Perles, R.)

22

23 ABSTRACT

24 The overconsumption of sucrose is closely related to sugar-sweetened beverages and
25 one of the main factors associated with the increase of metabolic diseases, such as type
26 2 diabetes, obesity, and insulin resistance. So, the addition of alternative sweeteners to
27 new fruit-based drinks could contribute to minimizing the incidence or severity of these
28 pathologies. Nevertheless, current knowledge on the influence of these additives on the
29 bioactive compounds present in these beverages is still scarce. Hence, to contribute to
30 the understanding of this issue, the plasma concentration of phenolic compounds
31 (anthocyanins and flavanones), after the ingestion of a new maqui-citrus-based
32 beverage, supplemented with sucrose (natural high caloric), stevia (natural non-caloric),
33 or sucralose (artificial non-caloric), was evaluated as evidence of their intestinal
34 absorption and metabolism previous to renal excretion. The beverages were ingested by
35 volunteers (n=20) and the resulting phenolic metabolites in plasma were analyzed by
36 UHPLC-ESI-MS/MS. A total of 13 metabolites were detected: caffeic acid sulfate,
37 caffeic acid glucuronide, 3,4-dihydroxyphenylacetic, 3,4-dihydroxyphenylacetic sulfate,
38 3,4-dihydroxyphenylacetic acid di-sulfate, 3,4-dihydroxyphenylacetic di-glucuronide, 3,4-
39 dihydroxyphenylacetic glucuronide-sulfate, *trans*-ferulic acid glucuronide, naringenin
40 glucuronide, vanillic acid, vanillic acid sulfate, vanillic acid glucuronide-sulfate, and
41 vanillic acid di-glucuronide, being recorded their maximum concentration after 30-60
42 minutes. In general, sucralose provided the greatest absorption value for most of these
43 metabolites, followed by stevia. Due to this, the present study proposes sucralose and
44 stevia (non-caloric sweeteners) as valuable alternatives to sucrose (high caloric
45 sweetener), to avoid the augmented risk of several metabolic disorders.

46 *Keywords:* Anthocyanins; Flavanones; Stevia; sucralose; sucrose; Metabolites; UHPLC-
47 ESI-MS/MS

48 *Abbreviations:* BMI, body mass index; CA, caffeic acid; CAT, catechol; Cy, Cyanidin;
49 DHPAA, 3,4-dihydroxyphenylacetic acid; DM2, diabetes mellitus 2; Dp, delphinidin;
50 E, eriodictyol; ESI, electrospray ionization; GA, gallic acid; Glc, glucoside; Glu,
51 glucuronide; H, hesperetin; HA, hippuric acid; HE, homoeriodictyol; MRM, multiple
52 reaction monitoring; N, naringenin; TFA, *trans*-ferulic acid; THBA, 2,4,6-
53 trihydroxybenzaldehyd; TIFA, *trans*-isoferulic acid; VA, vanillic acid; WHO, World
54 Health Organization.

55

Journal Pre-proof

56 **1. Introduction**

57 Changes in dietary habits, set-up during the last decades, have been associated
58 with an increased incidence of obesity and type 2 Diabetes Mellitus (DM2). One factor
59 critically related to this metabolic disorder is the overconsumption of sucrose, which is
60 closely linked to sugar-sweetened beverages [1].

61 In this scenario, the World Health Organization (WHO), jointly with other
62 institutions, has called for regulations that could reduce the intake of sugar, including
63 the regulation of the composition of marketable sweetened beverages. Due to this, the
64 lookout for alternative sweeteners and the elaboration of healthy beverages has become
65 a cornerstone to control risk factors associated with obesity and DM2 [2].

66 According to this growing awareness, fruit beverages fit the current trend of
67 increasing the consumption of bioactive compounds that have an array of health
68 benefits, contributing to prevent the incidence and severity of diverse diseases
69 associated with sugar consumption [3]. However, the bioavailability of these phenolic
70 compounds is generally low (up to 10% of the total intake) concerning non-esterified
71 compounds, although when considering the derivatives formed as a result of the phase
72 II reactions and the colonic metabolism, bioavailability ranges between 60% and 70%.
73 Indeed, the variation of the bioavailability values is strongly conditioned by the inter-
74 individual variability in terms of intestinal absorption and metabolism, as well as by the
75 physicochemical properties of the food/beverage matrices [4]. In this regard, the health
76 benefits associated to the consumption of these beverages have raised the incorporation
77 in diets of natural sources of bioactive phytochemicals, being citrus fruits considered as
78 a specially valuable ingredient in the development of functional beverages [3,5], as they
79 are rich in flavanones (e.g. narirutin, eriocitrin, neohesperidin, and hesperidin), as well
80 as other phenolic compounds.

81 Besides citrus fruits, Maqui berry (*Aristotelia chilensis* (Mol.) Stuntz), has been
82 also widely used in the development of functional beverages, based on its value as a
83 source of bioavailable and bioactive compounds, such as anthocyanins, represented by
84 eight different derivatives of cyanidin and delphinidin [6].

85 Based on these antecedents, these two fruits (citrus juices and maqui berry) have
86 been promoted as interesting ingredients for the development of new functional
87 beverages [7–9]. However, additional information and a deeper understanding regarding
88 the influence of alternative sweeteners on the pharmacokinetics of the bioactive
89 compounds are still needed.

90 Therefore, the present article is aimed at uncovering the influence of diverse
91 sweeteners, including sucrose (natural high caloric), stevia (natural non-caloric), and
92 sucralose (artificial non-caloric), on the plasma concentration of flavanones and
93 anthocyanins in healthy, overweight, humans, after the acute intake of (poly)phenol-rich
94 beverages developed on the base of these fruits. The sweeteners assessed in this work
95 were selected to compare a classical, natural, and high caloric sweetener (sucrose) and
96 two non-caloric alternatives (sucralose, an artificial, non-caloric, and widely used
97 sweetener and stevia, a natural emergent sweetener). The assessment of the
98 concentration of these phenolic compounds and their metabolites in plasma is strongly
99 motivated by the previous description of the urinary concentration in volunteers, which
100 demonstrated critical differences between sweeteners [8,9]. Also, the analysis of the
101 plasma concentration of these compounds will provide valuable information on the
102 delay of their intestinal absorption after consumption, as well as about the identity of the
103 circulating metabolites responsible for the biological attributions), which can differ
104 from those excreted by the urine.

105

106 2. Material and methods

107 2.1. Chemicals and reagents

108 Cyanidin (Cy) 3-*O*-glucoside, delphinidin (Dp) 3-*O*-glucoside, eriodictyol (E),
109 homoeriodictyol (HE), naringenin, and hesperetin were purchased from TransMIT
110 (Geiben, Germany). Narirutin, hesperidin, eriocitrin, caffeic (CA; also known as 3,4-
111 dihydroxycinnamic acid), gallic (GA; also known as 3,4,5-trihydroxybenzoic acid), 3,4-
112 dihydroxyphenylacetic (DHPAA), hippuric (HA), trans-ferulic (TFA; also known as 4-
113 hydroxy-3-methoxycinnamic acid), trans-isoferulic (TIFA; also known as 3-hydroxy-4-
114 methoxycinnamic acid), and vanillic (VA; also known as 4-hydroxy-3-methoxybenzoic
115 acid) acids, 2,4,6-trihydroxybenzaldehyd (THBA), and catechol (CAT; also known as
116 benzene-1,2-diol) were obtained from Sigma Aldrich (St. Louis, USA). Formic acid and
117 acetonitrile of analytical grade were obtained from Fisher-Scientific (Loughborough,
118 UK). All solutions were prepared with ultrapure deionized water from a Milli-Q
119 Advantage A10 ultrapure water purification system (Millipore, Burlington, MA, USA).

120

121 2.2. Beverages production and characterization on the (poly)phenolic content

122 Fresh dry organic maqui powder was provided by Maqui New Life S.A.
123 (Santiago, Chile). Cítricos de Murcia S.L. (Murcia, Spain) and AMC Grupo
124 Alimentación Fresco y Zumos S.A. (Murcia, Spain) supplied the citrus juices. Sucrose
125 was obtained from AB Azucarera Iberia S.L. (Madrid, Spain), Stevia from AgriStevia
126 S.L. (Murcia, Spain), and Sucralose from Zukan (Murcia, Spain).

127 Maqui-citrus beverages were processed as previously described [8,9]. Briefly,
128 maqui powder was mixed with citrus juices to obtain the base drink. Then, the three
129 selected sweeteners were added, to obtain the different beverages, and pasteurized by

130 applying 85 °C during 58 seconds. Afterward, the mixtures were bottled and stored at
131 5 °C until being consumed by the volunteers.

132 Maqui-citrus drinks were characterized on their (poly)phenolic composition
133 following the methodology previously described [7,10]. Beverages were centrifuged at
134 10500 rpm, during 5 min (Sigma 1-13, B. Braun Biotech International, Osterode,
135 Germany). The supernatants were filtered through a 0.45 µm PVDF membrane (Millex
136 HV13, Millipore, Bedford, Mass., USA) and analyzed by RT-HPLC-DAD. The
137 chromatographic analyses were carried out on a Luna 5 µm C₁₈(2)100 Å column
138 (250.0 x 4.6 mm), using Security Guard Cartridges PFD 4.0 x 3.0 mm both supplied by
139 Phenomenex (California, USA), using 5% formic acid in deionized Milli-Q water
140 (solvent A) and 100% methanol (solvent B), upon the linear-gradient (time, %B)
141 (0, 15%); (20, 30%); (30, 40%); (35, 60%); (40, 90%); (44, 90%); (45, 15%), and (50,
142 15%), using an Agilent Technologies 1220 Infinity Liquid Chromatograph, equipped
143 with an auto-injector (G1313, Agilent Technologies) and a Diode Array Detector (1260,
144 Agilent Technologies, California, USA). Chromatograms were recorded and processed
145 on an Agilent ChemStation for LC 3D systems. The volume of injection and flow rate
146 were 10 µL and 0.9 mL/min, respectively. The quantification of flavanones and
147 anthocyanins was done on UV chromatograms recorded at 280 nm as hesperidin and
148 520 nm as cyanidin 3-*O*-glucoside, respectively, and expressed as mg per 100 mL of
149 juice (mg/100 mL).

150

151 2.3. *Experimental design*

152 A double-blind, randomized, cross-over clinical study has been conducted in
153 overweight individuals (n=20), by the Catholic University of Murcia (Murcia, Spain).
154 The study and protocol were approved by the Official Ethical Committee of Clinical

155 Studies (CEIC) of University Hospital ‘Morales Meseguer’ (Murcia) and registered at
156 ClinicalTrials.gov (NCT04016337). The volunteers provided written consent to
157 participate in this study. The criteria for volunteers’ selection to participate in the study
158 were to be in good health, overweight (body mass index (BMI) between 24.9 and
159 29.9 kg/m² following WHO criteria), aged 40-60 years, non-smokers, non-affected by
160 dyslipidemia, and normotensive, with no chronic illnesses and no taking any
161 medication. After an initial phase of 3 days of wash-out with a (poly)phenols free and
162 added sugar-free diet, 330 mL of the test drinks (stevia, sucralose, or sucrose added
163 sweetener) were administered on fasting conditions. Plasma samples were collected
164 before the beverage ingestion (0 min point), as well as in the following times: 30, 60,
165 and 210 min. After 15 days, the process was repeated, for each volunteer ingesting
166 another drink developed with remaining sweeteners until all types of drink were
167 consumed by all the volunteers (3 rounds). Plasma samples collected were stored at -
168 80°C until analyses that were performed once each period was finished and in the same
169 batch to minimize analytical variations.

170

171 2.4. Plasma samples collection, processing, and analysis by UHPLC-ESI-MS/MS

172 The plasma extraction procedure was applied according to the methodology
173 previously described [8,9]. Briefly, plasma samples were defrosted and diluted in
174 acetonitrile/formic acid (98:2, v/v) 1:2,5 (v/v), vortex for 1 min, sonicated for 10 min,
175 and centrifuged at 15000 g for 10 min, at 5 °C (Sigma 1-16, B. Braun Biotech
176 International, Osterode, Germany). Afterward, supernatants were concentrated in a
177 speed vacuum concentrator and reconstituted in 200 µL methanol/Milli-Q-water 0.2%
178 formic acid (v/v) (50:50, v/v). Later on, the samples were centrifuged at 15000 g for 10

179 min, at 5°C (Sigma 1-16, B. Braun Biotech International, Osterode, Germany), and
180 stored at -20°C until analysis by UHPLC-ESI-MS/MS.

181 The identification and quantification of phenolic metabolites was performed by
182 applying the methodology previously reported, with optimized injected volume, flow
183 rate, and MS parameters, by comparison with freshly prepared standards curves of the
184 different phenolics [8,9,11]. The analysis of the samples on the profile and
185 concentration of phenolic metabolites was carried out on a chromatographic column
186 Ascentis Express F5 (50 x 2.1 mm; 2.7 µm pore size) (Sigma, Osterode, Germany). The
187 solvents used for the chromatographic separation were deionized Milli-Q water/formic
188 acid (99.9:0.1, v/v) (solvent A) and acetonitrile/formic acid (99.9:0.1, v/v) (solvent B),
189 upon the linear-gradient (time, %B) (0, 10%); (1, 10%); (10, 60%); (11, 80%); (13,
190 80%); (13.01, 10%), and (14.50, 10%); using an UHPLC system coupled with a triple
191 quadrupole tandem mass spectrometer, model 6460 (Agilent Technologies, Waldbronn,
192 Germany), operated in multiple reaction monitoring (MRM) and negative/positive
193 electrospray ionization (ESI) modes. The volume injected and flow rate were 10 µL and
194 0.2 mL/min, respectively. The MS parameters, at the optimized conditions, were gas
195 temperature 325 °C; gas flow 10 L/min; nebulizer 40 psi; sheath gas heater 275 °C;
196 sheath gas flow 12; capillary voltage 4000–5000 V; Vcharging 1000–2000. Data
197 acquisition and processing were performed by using MassHunter software version
198 B.08.00 (Agilent Technologies, Walbronn, Germany) (Table 3). Regarding the
199 quantification of the diverse compounds identified, values of area providing signal to
200 noise ratio lower than 1/3, established as the consensus criteria for the limit of detection
201 (LOD), were considered and in consequence values lower than LOD were neither
202 identified nor quantified.

203

204

205 2.5. *Statistical analysis*

206 Quantitative data are presented as mean \pm SD of 20 volunteers. Specific
207 differences were examined by a Repeated Measure (RM) Multivariate analysis of
208 variance (ANOVA) as the statistical analysis of election for a number of dependent
209 variables higher than 2, measured as correlated, which is used when measuring the
210 effect of an intervention (*e.g.*, a dietary intervention) at different time points. This
211 statistical model allows testing the main effects within and between the subjects,
212 interaction effects between factors, and covariate effects, as well as the effects of
213 interactions between covariates and between subject factors. The data were processed
214 using the SPSS 21.0 software package (SPSS Inc., Chicago, Ill., U.S.A.) and the level of
215 significance was set-up at $p < 0.05$.

216

217 **3. Results and discussion**218 3.1. *Flavanone and anthocyanin content of beverages*

219 The quantitative profile of the juices regarding the phenolic compounds was set
220 up, to establish the flavanones and anthocyanins present in the maqui-citrus beverages
221 developed using three different sweeteners (stevia, sucralose, and sucrose) and thus,
222 susceptible to be absorbed in the intestine after their dietary ingestion. In this regard, it
223 was observed the presence of the four following flavanones: hesperidin (hesperetin 7-*O*-
224 rutinoside) that presented the highest concentration (4.87 mg/100 mL, on average),
225 followed by narirutin (naringenin 7-*O*-rutinoside; 1.31 mg/100 mL, on average),
226 eriocitrin (eriodictyol 7-*O*-rutinoside, 0.32 mg/100 mL, on average), and *O*-triglycosyl-
227 naringenin with the lowest concentrations (0.14 mg/100 mL, on average). On the other
228 hand, anthocyanins were found in higher amounts, being Dp 3,5-*O*-di-glc the

229 predominant (3.49 mg/100 mL, on average), followed by Dp 3-*O*-sam-5-*O*-glc
230 (3.15 mg/100 mL, on average), Dp 3-*O*-glc (2.93 mg/100 mL, on average), Cy 3-*O*-
231 sam-5-*O*-glc and Cy 3,5-*O*-di-glc (1.48 mg/100 mL, on average), Dp 3-*O*-sam
232 (1.10 mg/100 mL, on average), Cy 3-*O*-glc (0.55 mg/100 mL, on average), and Cy 3-*O*-
233 sam (0.40 mg/100 mL, on average). No statistically significant differences ($p>0.05$)
234 were observed between the flavanone and anthocyanin contents of the different maqui-
235 citrus drinks when considering individual or total flavanones (Tables 1 and 2).

236

237 3.2. *Qualitative analysis of plasma metabolites of flavanones and anthocyanins of the* 238 *maqui-citrus beverage*

239 To profile the diversity of citrus flavanones and maqui-berry anthocyanins
240 absorbed at the intestinal level and subsequently present in plasma, samples were
241 collected before and after the ingestion of 330 mL of the diverse beverages at different
242 times, and processed to identify possible differences between the three beverages (with
243 stevia, sucralose, or sucrose added). Based on previous researches [8,9], metabolites
244 already described in urine after the ingestion of similar juices were looked for. Upon
245 this strategy, 30 phenolic metabolites derived from flavanones and anthocyanins, were
246 detected in plasma (Table 3). More specifically, the compounds identified in plasma
247 were eriodictyol (E), eriodictyol glucuronide (E glu), eriodictyol sulfate (E sulfate),
248 homoeriodictyol glucuronide (HE glu), homoeriodictyol glucuronide-sulfate (HE glu-
249 sulfate), naringenin (N), *O*-triglycosyl-naringenin and naringenin glucuronide (N glu),
250 regarding flavanones. In addition, it was also identified the presence of caffeic acid
251 glucuronide (CA glu), caffeic acid sulfate (CA sulfate), caffeic acid glucuronide-sulfate
252 (CA glu-sulfate), 3,4-dihydroxyphenylacetic acid (DHPAA), 3,4-dihydroxyphenylacetic
253 acid glucuronide (DHPAA glu), 3,4-dihydroxyphenylacetic acid di-glucuronide

254 (DHPAA di-glu), 3,4-dihydroxyphenylacetic acid sulfate (DHPAA sulfate), 3,4-
255 dihydroxyphenylacetic acid glucuronide-sulfate (DHPAA glu-sulfate), 3,4-
256 dihydroxyphenylacetic acid di-sulfate (DHPAA di-sulfate), hippuric acid (HA),
257 hippuric acid sulfate (HA sulfate), hippuric acid glucuronide-sulfate (HA glu-sulfate),
258 trans-ferulic acid (TFA), trans-ferulic acid glucuronide (TFA glu), trans-ferulic acid di-
259 sulfate (TFA di-sulfate), 2,4,6-trihydroxybenzaldehyde (THBA), 2,4,6-
260 trihydroxybenzaldehyde sulfate (THBA sulfate), trans-isoferulic acid (TIFA), vanillic
261 acid (VA), vanillic acid di-glucuronide (VA di-glu), vanillic acid sulfate (VA sulfate)
262 and vanillic acid glucuronide-sulfate (VA glu-sulfate), concerning anthocyanins. These
263 phenolic compounds were tentatively identified according to their retention time,
264 molecular masses, and fragmentation pattern according to the information available in
265 the literature [11].

266 Although hesperidin (hesperetin 7-rutinoside) was the most abundant flavanone in
267 the beverages, accounting for 73.3% of total flavanones, neither this flavanone nor its
268 phase II derivatives (H glu, H sulfate, H glu-sulfate, H di-glu and H di-sulfate) were
269 observed in plasma in concentrations higher than the limit of detection of the method.
270 Also, none of the precursor anthocyanins (Dp and Cy aglycones) were found in the
271 plasma samples analyzed. The lack of a proper identification of these anthocyanins in
272 plasma could be attributed to their degradation during the gastrointestinal digestion
273 process, as well as due to their low absorption rate at the intestinal level, especially
274 because of the intestinal absorption mechanisms of anthocyanin glycosides are still
275 speculative. Moreover, in some extent the fraction of these compounds absorbed at
276 intestinal level could suffer the metabolism of the epithelial cells and hepatocytes giving
277 rise to phase II derivatives [12]. In this aspect, it has been recently demonstrated that the
278 metabolism of the precursor, towards different degradation metabolites, depends on the

279 metabolic traits of the volunteers and the inter-individual variation [13]. So that, most
280 metabolites detected (E, E glu, E sulfate, HE glu, HE glu-sulfate, N, N glc, CA glu-
281 sulfate, DHPAA glu, HA sulfate, HA glu-sulfate, TFA, TFA di-sulfate, THBA, THBA
282 sulfate and TIFA) were found in a reduced number of volunteers in a quantifiable
283 amount, turning them into non-representative, and reinforcing the relevance of the
284 biological features inherent to each volunteer for the final bioavailability of
285 (poly)phenols. Moreover, the dispersion detected in the quantitative profile of plasma
286 metabolites, enclosed to the inter-individual variation, would make difficult to find
287 significant differences between beverages.

288 On the other hand, N glu, CA glu, CA sulfate, DHPAA, DHPAA di-glu, DHPAA
289 sulfate, DHPAA glu-sulfate, DHPAA di-sulfate, HA, TFA glu, VA, VA di-glu, VA
290 sulfate, and VA glu-sulfate were identified and quantified in plasma of all volunteers.
291 However, HA was not considered because of its high background levels, probably
292 originated from other dietary and endogenous sources, making the determination of the
293 amounts coming from the metabolism of anthocyanins difficult [14].

294

295 3.3. *Quantitative profile of flavanone and anthocyanin metabolites in plasma*

296 The quantification of circulating metabolites was developed on basal plasma
297 (0 minutes), as well as on plasma at 30, 60, and 210 minutes. The kinetic for the above-
298 referred metabolites exhibited the highest concentration at 30-60 min in plasma, after
299 the intake of the beverages, according to previous studies [15], suggesting that
300 sweeteners do not change the absorption kinetic of flavonoids. For this reason, all
301 concentrations described are referred to as that time-points (Fig. 1).

302 The content of N glu in plasma was 0.10 $\mu\text{g/mL}$, for those volunteers that ingested
303 stevia as sweetener. This concentration was higher than the reached when using

304 sucralose and sucrose, which displayed concentrations ~25% lower, on average, in
305 comparison with beverages done using sucralose (Fig. 1). Despite these differences
306 between sweeteners, the application of the RM ANOVA allowed identifying significant
307 augments regarding the concentration of N glu at min 30 ($p<0.05$) for juices developed
308 using stevia as sweetener.

309 The amount of whole phase II derivatives of CA recorded was 0.37 ng/mL after
310 the intake of sucralose-sweetened beverages, being a 29% higher, on average, than the
311 provided after the intake of beverages prepared using stevia and sucrose as sweeteners.
312 When analyzing the effect of the sweetener regarding the individual compounds, for CA
313 glu and CA sulfate, the highest values corresponded to juices developed using sucralose
314 as sweetener, which gave rise to plasma concentrations of 0.22 and 0.07 ng/mL,
315 respectively. These concentrations were ~36% higher than those reached when using
316 stevia and sucrose. (Fig. 1). Summarizing the effect of consuming the juices under
317 evaluation, the only phase II derivative of CA that increased significantly its
318 concentration in peripheral blood plasma 30 and 60 min after the dietary intervention,
319 according with the RM ANOVA was CA glu ($p<0.05$ and $p<0.01$, respectively for
320 stevia and both time points significant at $p<0.05$ for sucrose and sucralose).

321 Moreover, sucrose was the sweetener that provided the highest plasma
322 concentration for the sum of DHPAA and their phase II metabolites (2.44 ng/mL),
323 which was ~36% higher than the reached when using sucralose and stevia. For DHPAA
324 di-glu, DHPAA glu-sulfate and DHPAA di-sulfate, the highest value corresponded to
325 the juices developed with added stevia (0.58; 0.19 and 0.29 ng/mL, respectively).
326 Nevertheless, for DHPAA sulfate, the beverages elaborated with sucrose were the ones
327 that provided the highest concentration in plasma, 1.42 ng/mL. The intake of sucralose
328 sweetened juices rendered a higher plasma concentration than the other sweeteners for

329 DHPAA, 0.33 ng/mL. In this case, when comparing the sweetened beverage which
330 provided the highest bioavailability for each compound against the remaining ones, the
331 intestinal absorption rates were ~34% lower, for DHPAA and their phase II metabolites
332 considered individually (Fig. 1). The only significant increase of the basal plasma
333 concentration was retrieved for DHPAA di-sulfate at 30 and 60 min after the ingestion
334 of juices elaborated using sucrose and sucralose as sweeteners ($p<0.05$).

335 Regarding TFA glu, stevia-sweetened juices provided the highest plasma
336 concentration (0.81 ng/mL), which resulted in a 75% higher, on average, than the
337 obtained after the ingestion of sucrose- and stevia-sweetened beverages.

338 The sum of the plasma concentration of VA and its phase II derivatives provided
339 values of 6.13 ng/mL, in volunteers ingesting sucralose-sweetened juices, while the
340 beverages developed based on stevia and sucrose gave rise to plasma concentrations
341 57% lower values, on average. When considering individual metabolites, for VA di-glu,
342 VA sulfate, and VA glu-sulfate, the highest value corresponded to sucralose-sweetened
343 juices, with the average plasma concentration values 1.93, 1.45 and 2.38 ng/mL,
344 respectively. However, for VA, stevia-based drinks displayed the highest concentrations
345 (0.81 ng/mL) (Fig. 1). Although, the dispersion of the values recorded as a result of
346 inter-individual variability did not allow retrieving significant differences between
347 sweeteners when applying the one-way ANOVA and Duncan's multiple range tests
348 [16], when analyzing the increase caused by the separate sweeteners using MR
349 ANOVA, it was observed that non-esterified VA and total VA experienced a significant
350 augment after 60 min ($p<0.05$) for stevia-sweetened beverages.

351 As overall, results, described on the intestinal absorption of flavanones and
352 anthocyanins after the intake of the developed beverages, indicated that stevia and
353 sucralose were the most efficient sweeteners, regarding the plasma concentrations

354 achieved for most flavanone and anthocyanin metabolites (N glu, DHPAA di-glu,
355 DHPAA glu-sulfate, DHPAA di-sulfate, TFA glu and VA, for stevia; CA glu, CA
356 sulfate, DHPAA, VA di-glu, VA sulfate and VA glu-sulfate, for sucralose), while
357 sucrose only provided significantly higher concentrations of DHPAA sulfate. These
358 differences could be attributable to the central role of intestinal sugar transporters in the
359 absorption of flavonoids, as well as to the competence events that could be established
360 between the separate sweeteners used and the phenolic compounds found [12]. In this
361 regard, the central role of the sugar transporters in the absorption of phenolic
362 compounds has been established on the base of characterizing the influence of the
363 attached sugar in esterified phenolics that also condition strongly their solubility in the
364 intestinal mucus as part of the mechanism of polyphenols absorption, as described for
365 catechins, flavanones or phenolic acids [17]. However, the gap of knowledge on the
366 effects of other components of foods, such as sweeteners present in manufactured
367 products, on the bioavailability of polyphenols are underexplored, being required
368 additional human studies to set-up the general principles affecting absorption *in vivo*.

369 Thus, these results suggest that both stevia and sucralose were better than sucrose
370 in terms of intestinal absorption of citrus and maqui phenolics. In this aspect, several
371 studies, describing the effects on human health and metabolic diseases of stevia and
372 sucralose, have reported contradictory results as extensively reviewed by Daher et al.
373 [18]. In this case, the majority of these interventional studies are focused on non-
374 nutritional sweeteners isolated, the reason why the interaction of sweeteners with diet
375 remains underexplored [18].

376 The interest of establishing the pharmacokinetic features of (poly)phenols in
377 functional beverages is supported by their widely recognized biological benefits in
378 humans, as a result of their dietary ingestion. In this regard, to the present date, several

379 studies have suggested the cardioprotective activity of hesperidin and its aglycone,
380 hesperetin (H) [4,19,20]. Besides, a study carried out on adults affected by metabolic
381 syndrome revealed that the dietary ingestion of 500 mg hesperidin per day, for three
382 weeks, improves the endothelial function and reduces the level of inflammatory markers
383 [21]. On the other hand, anthocyanins are featured by valuable biological properties,
384 including high radical scavenging activity, and the capacity to protect humans against
385 risk factors for cardiovascular diseases and to inhibit adipogenesis, inflammation, and
386 diabetes symptoms [6,22]. Also, recent meta-analyses of prospective cohort studies
387 have evidenced that the dietary intake of anthocyanins reduces the risk of DM2 and
388 cardiovascular disease, thus providing vascular benefits [23].

389

390 **4. Conclusions**

391 The results obtained in the present work shed light on the absorption ratio for
392 berry anthocyanins and citrus flavanones, as well as a variety of phase II derivatives,
393 resulting from the gastrointestinal process on these phenolic compounds. This is of
394 special relevance because of the protective attributions of these compounds against
395 cardiovascular diseases, and to decrease the severity of inflammatory processes and
396 diabetes symptoms. The results obtained suggested that the greatest bioavailability for
397 most of these metabolites was provided by stevia and sucralose, while, sucrose showed
398 higher bioavailability only in 1 out of the 13 metabolites analyzed. So, considering the
399 significantly different bioavailability achieved when ingesting beverages developed
400 using the three sweeteners, this study proposes sucralose and stevia (non-caloric
401 sweeteners) as valuable alternatives to sucrose (high caloric sweetener), which
402 consumption has been associated to an augmented risk of DM2, obesity, and other
403 metabolic disorders. Moreover, since this work shows promising results based in an

404 acute intervention study, the development of an intervention assay addressed to set-up
405 the effect of the chronic ingestion of the best juices according to our results could be
406 interesting to understand more about the effects on human health of the two alternatives.

407 **Acknowledgements**

408 This work was funded by the Spanish MINECO through Research Project AGL2016-
409 75332-C2-1-R (AEI/FEDER, UE). V.A. was supported by FPI (BES-2017-079754)
410 grant of the Fellowship Program from the Spanish Ministry of Science, Innovation, and
411 Universities (MICIU).

412

413 **References**

- 414 [1] Julie R. Palmer MS; Supriya Krishnan, DSc; Frank B. Hu, MD; Martha Singer, MPH; Lynn
415 Rosenberg, ScD SDAB. Sugar-Sweetened Beverages and Incidence of Type 2 Diabetes Mellitus
416 in African American Women. *Arch Intern Med* 2008;168(14):1487–92.
- 417 [2] Popkin BM, Adair LS, Ng SW. Global nutrition transition and the pandemic of obesity in
418 developing countries. *Nutr Rev* 2012;70:3–21. <https://doi.org/10.1111/j.1753-4887.2011.00456.x>.
- 419 [3] Amiot MJ, Riva C, Vinet A. Effects of dietary polyphenols on metabolic syndrome features in
420 humans: a systematic review. *Obes Rev* 2016;17:573–86. <https://doi.org/10.1111/obr.12409>.
- 421 [4] Barreca D, Gattuso G, Bellocco E, Calderaro A, Trombetta D, Smeriglio A, et al. Flavanones:
422 Citrus phytochemical with health-promoting properties. *BioFactors* 2017;43:495–506.
423 <https://doi.org/10.1002/biof.1363>.
- 424 [5] Gonzalez-Molina E, Dominguez-Perles R, Moreno DA, Garcia-Viguera C. Natural bioactive
425 compounds of Citrus limon for food and health. *J Pharm Biomed Anal* 2010;51:327–45.
426 <https://doi.org/10.1016/j.jpba.2009.07.027>.
- 427 [6] Girones-Vilaplana A, Mena P, Moreno DA, Garcia-Viguera C. Evaluation of sensorial,
428 phytochemical and biological properties of new isotonic beverages enriched with lemon and
429 berries during shelf life. *J Sci Food Agric* 2014;94:1090–100. <https://doi.org/10.1002/jsfa.6370>.
- 430 [7] Gironés-Vilaplana A, Mena P, García-Viguera C, Moreno DA. A novel beverage rich in
431 antioxidant phenolics: Maqui berry (*Aristotelia chilensis*) and lemon juice. *Lwt* 2012;47:279–86.

- 432 <https://doi.org/10.1016/j.lwt.2012.01.020>.
- 433 [8] Agulló V, Villaño D, García-Viguera C, Domínguez-Perles R. Anthocyanin metabolites in human
434 urine after the intake of new functional beverages. *Molecules* 2020;25.
435 <https://doi.org/10.3390/molecules25020371>.
- 436 [9] Agulló V, Domínguez-Perles R, Moreno DA, Zafrilla P, García-Viguera C. Alternative
437 sweeteners modify the urinary excretion of flavanones metabolites ingested through a new maqui-
438 berry beverage. *Foods* 2020;9. <https://doi.org/10.3390/foods9010041>.
- 439 [10] Salar FJ, Agulló V, García-Viguera C, Domínguez-Perles R. Stevia vs. Sucrose: Influence on the
440 phytochemical content of a citrus–maqui beverage—a shelf life study. *Foods* 2020;9.
441 <https://doi.org/10.3390/foods9020219>.
- 442 [11] Medina S, Domínguez-Perles R, García-Viguera C, Cejuela-Anta R, Martínez-Sanz JM, Ferreres
443 F, et al. Physical activity increases the bioavailability of flavanones after dietary aronia-citrus
444 juice intake in triathletes. *Food Chem* 2012;135. <https://doi.org/10.1016/j.foodchem.2012.07.080>.
- 445 [12] Kay CD, Pereira-Caro G, Ludwig IA, Clifford MN, Crozier A. Anthocyanins and Flavanones Are
446 More Bioavailable than Previously Perceived: A Review of Recent Evidence. *Annu Rev Food Sci*
447 *Technol* 2017;8:155–80. <https://doi.org/10.1146/annurev-food-030216-025636>.
- 448 [13] Bento-Silva A, Koistinen VM, Mena P, Bronze MR, Hanhineva K, Sahlstrøm S, et al. Factors
449 affecting intake, metabolism and health benefits of phenolic acids: do we understand individual
450 variability? *Eur J Nutr* 2020;59:1275–93. <https://doi.org/10.1007/s00394-019-01987-6>.
- 451 [14] Ludwig IA, Mena P, Calani L, Borges G, Pereira-Caro G, Bresciani L, et al. New insights into the
452 bioavailability of red raspberry anthocyanins and ellagitannins. *Free Radic Biol Med*
453 2015;89:758–69. <https://doi.org/10.1016/j.freeradbiomed.2015.10.400>.
- 454 [15] Mueller D, Jung K, Winter M, Rogoll D, Melcher R, Richling E. Human intervention study to
455 investigate the intestinal accessibility and bioavailability of anthocyanins from bilberries. *Food*
456 *Chem* 2017;231:275–86. <https://doi.org/10.1016/j.foodchem.2017.03.130>.
- 457 [16] Fang J. Bioavailability of anthocyanins. *Drug Metab Rev* 2014;46:508–20.
458 <https://doi.org/10.3109/03602532.2014.978080>.
- 459 [17] Scholz S, Williamson G. Interactions affecting the bioavailability of dietary polyphenols in vivo.
460 *Int. J. Vitam. Nutr. Res.*, vol. 77, *Int J Vitam Nutr Res*; 2007, p. 224–35.
461 <https://doi.org/10.1024/0300-9831.77.3.224>.

- 462 [18] Daher MI, Matta JM, Abdel Nour AM. Non-nutritive sweeteners and type 2 diabetes: Should we
463 ring the bell? *Diabetes Res Clin Pr* 2019;155:107786.
464 <https://doi.org/10.1016/j.diabres.2019.107786>.
- 465 [19] Kim J, Wie MB, Ahn M, Tanaka A, Matsuda H, Shin T. Benefits of hesperidin in central nervous
466 system disorders: A review. *Anat Cell Biol* 2019;52:369–77. <https://doi.org/10.5115/acb.19.119>.
- 467 [20] Pla-Paga L, Companys J, Calderon-Perez L, Llauro E, Sola R, Valls RM, et al. Effects of
468 hesperidin consumption on cardiovascular risk biomarkers: A systematic review of animal studies
469 and human randomized clinical trials. *Nutr Rev* 2019;77:1–20.
470 <https://doi.org/10.1093/nutrit/nuz036>.
- 471 [21] Rizza S, Muniyappa R, Iantorno M, Kim JA, Chen H, Pullikotil P, et al. Citrus polyphenol
472 hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial
473 function and reducing inflammatory markers in patients with metabolic syndrome. *J Clin
474 Endocrinol Metab* 2011;96:782–92. <https://doi.org/10.1210/jc.2010-2879>.
- 475 [22] Bastías-Montes JM, Monterrosa K, Muñoz-Fariña O, García O, Acuña-Nelson SM, Vidal-San
476 Martín C, et al. Chemoprotective and antiobesity effects of tocopherols from seed oil of Maqui-berry:
477 Their antioxidative and digestive enzyme inhibition potential. *Food Chem Toxicol*
478 2020;136:111036. <https://doi.org/10.1016/j.fct.2019.111036>.
- 479 [23] García-Conesa MT, Chambers K, Combet E, Pinto P, Garcia-Aloy M, Andrés-Lacueva C, et al.
480 Meta-analysis of the effects of foods and derived products containing ellagitannins and
481 anthocyanins on cardiometabolic biomarkers: Analysis of factors influencing variability of the
482 individual responses. *Int J Mol Sci* 2018;19. <https://doi.org/10.3390/ijms19030694>.
- 483

484 **FIGURE CAPTIONS**

485 **Fig. 1.** Content (mean \pm SD, n=20) of single flavonoid metabolites in basal peripheral
486 blood plasma and plasma obtained, from healthy overweight volunteers, 30, 60, and 210
487 minutes after ingesting 330 mL of maqui-citrus beverages developed using stevia (\blacktriangle),
488 sucralose (\bullet), and sucrose (\blacksquare), as sweeteners.

489

Journal Pre-proof

490 TABLES

Table 1. Flavanone composition of the maqui-citrus juices.

Beverages	Flavanones ^Z (mg/100mL)				TOTAL
	O-triglycosyl-N	E 7-O-rutinoside	N 7-O-rutinoside	H 7-O-rutinoside	
Stevia	0.15 ± 0.02	0.32 ± 0.04	1.30 ± 0.01	4.87 ± 0.01	6.64 ± 0.2
Sucralose	0.14 ± 0.02	0.32 ± 0.01	1.31 ± 0.01	4.86 ± 0.01	6.63 ± 0.1
Sucrose	0.14 ± 0.01	0.31 ± 0.03	1.31 ± 0.01	4.88 ± 0.01	6.64 ± 0.1
<i>P</i> -value	>0.05 ^{N.s.}	>0.05 ^{N.s.}	>0.05 ^{N.s.}	>0.05 ^{N.s.}	>0.05 ^{N.s.}

^Z N, naringenin; E, eriodictyol; H, hesperetin.

491

Table 2. Anthocyanins composition of the maqui-citrus juices.

Beverages	Anthocyanins ^z (mg/100mL)								
	Dp 3- <i>O</i> -sam-5- <i>O</i> -glc	Dp 3,5- <i>O</i> -diglc	Cy 3- <i>O</i> -sam-5- <i>O</i> -glc		Dp 3- <i>O</i> -sam	Dp 3- <i>O</i> -glc	Cy 3- <i>O</i> -sam	Cy 3- <i>O</i> -glc	TOTAL
			+	Cy 3,5- <i>O</i> -di-glc					
Stevia	3.06 ± 0.12	3.59 ± 0.02	1.54 ± 0.02		1.09 ± 0.01	2.87 ± 0.02	0.40 ± 0.01	0.54 ± 0.01	13.1 ± 0.2
Sucralose	3.19 ± 0.05	3.51 ± 0.01	1.51 ± 0.01		1.11 ± 0.01	3.02 ± 0.01	0.41 ± 0.01	0.57 ± 0.01	13.3 ± 0.1
Sucrose	3.19 ± 0.01	3.36 ± 0.09	1.38 ± 0.01		1.09 ± 0.01	2.90 ± 0.01	0.40 ± 0.01	0.55 ± 0.01	12.9 ± 0.2
<i>P</i> -value	>0.05 ^{N.s.}	>0.05 ^{N.s.}	>0.05 ^{N.s.}		>0.05 ^{N.s.}	>0.05 ^{N.s.}	>0.05 ^{N.s.}	>0.05 ^{N.s.}	>0.05 ^{N.s.}

^z Cy, cyanidin; Dp, delphinidin; Glc, glucoside; Sam, sambubioside.

492

Table 3. Qualitative analysis of anthocyanin and flavanone metabolites in plasma after the ingestion of maqui-citrus juices determined by UHLC-ESI-QqQ-MS/MS operated in multiple reaction monitoring, in negative and positive ionization modes, respectively.

Compound	RT (min)	Precursor ion [M-H] ⁻ m/z	Product ion MS2 [M-H] ⁻ m/z	Fragmentation (V)	CE (eV)	Polarity
<i>Cyanidin metabolites</i>						
Cyanidin (Cy)	8.81 (<LOD)	287.0	137.0	100	20	Positive
Cy 3- <i>O</i> -glucoside	<LOD	449.0	287.0	100	20	Positive
Cy 3,5- <i>O</i> -di-glucoside	<LOD	743.0	287.0	100	20	Positive
Cy 3- <i>O</i> -sambubioside	<LOD	581.0	287.0	100	20	Positive
Cy 3- <i>O</i> -sambubioside-5- <i>O</i> -glucoside	<LOD	611.0	287.0	100	20	Positive
<i>Delphinidin metabolites</i>						
Delphinidin (Dp)	5.18 (<LOD)	303.0	229.0/257.0	100	20	Positive
Dp 3- <i>O</i> -glucoside	<LOD	465.0	303.0	100	20	Positive
Dp 3,5- <i>O</i> -di-glucoside	<LOD	627.0	303.0	100	20	Positive
Dp 3- <i>O</i> -sambubioside	<LOD	597.0	303.0	100	20	Positive
Dp 3- <i>O</i> -sambubioside-5- <i>O</i> -glucoside	<LOD	759.0	303.0	100	20	Positive
<i>Eriodictyol metabolites</i>						
Eriodictyol (E)	6.49	287.0	151.0	70	10	Negative
Eriocitrin	<LOD	449.0	287.0	70	10	Negative
E glucuronide	4.87	463.0	287.0	70	10	Negative
E di-glucuronide	<LOD	639.0	287.0	70	10	Negative
E sulfate	5.53	367.0	287.0	70	10	Negative
E di-sulfate	<LOD	447.0	287.0	70	10	Negative
E glucuronide-sulfate	<LOD	543.0	287.0	70	10	Negative
<i>Hesperetin metabolites</i>						
Hesperetin (H)	7.30 (<LOD)	302.0	151.0	70	20	Negative
Hesperidin	<LOD	609.0	302.0	70	20	Negative
H glucuronide	<LOD	478.0	302.0	70	20	Negative
H di-glucuronide	<LOD	664.0	302.0	70	20	Negative
H sulfate	<LOD	382.0	302.0	70	20	Negative
H di-sulfate	<LOD	462.0	302.0	70	20	Negative
H glucuronide-sulfate	<LOD	558.0	302.0	70	20	Negative
<i>Homoeriodictyol metabolites</i>						
Homoeriodictyol (HE)	7.30 (<LOD)	301.0	151.0	110	15	Negative
HE glucuronide	5.50	477.0	301.0	110	15	Negative
HE di-glucuronide	<LOD	653.0	301.0	110	15	Negative
HE sulfate	<LOD	381.0	301.0	110	15	Negative
HE di-sulfate	<LOD	461.0	301.0	110	15	Negative
HE glucuronide-sulfate	4.67	557.0	301.0	110	15	Negative
<i>Naringenin metabolites</i>						
Naringenin (N)	7.26	271.0	119.0	130	20	Negative
<i>O</i> -triglycosyl-N	4.63	433.0	271.0	130	20	Negative
Narirutin	<LOD	579.0	271.0	130	20	Negative
N glucuronide	5.07	433.0	271.0	130	20	Negative
N di-glucuronide	<LOD	623.0	271.0	130	20	Negative
N sulfate	<LOD	351.0	271.0	130	20	Negative
N di-sulfate	<LOD	431.0	271.0	130	20	Negative
N glucuronide-sulfate	<LOD	527.0	271.0	130	20	Negative

<LOD, lower than the limit of detection.

Table 3. Qualitative analysis of anthocyanin and flavanone metabolites in plasma after the ingestion of maqui-citrus juices determined by UHLC-ESI-QqQ-MS/MS operated in multiple reaction monitoring, in negative and positive ionization modes, respectively (*Cont.*).

<i>Caffeic acid metabolites</i>						
Caffeic acid (CA)	3.25 (<LOD)	179.1	135.0	70	15	Negative
CA glucuronide	2.40	355.1	179.1	70	15	Negative
CA di-glucuronide	1.67	531.1	179.1	70	15	Negative
CA sulfate	2.99	259.1	179.1	70	15	Negative
CA glucuronide-sulfate	1.95	435.1	179.1	70	15	Negative
CA di-Sulfate	<LOD	339.1	179.1	70	15	Negative
<i>Catechol metabolites</i>						
Catechol (CAT)	5.04 (<LOD)	109.0	67.0	80	6	Negative
CAT glucuronide	<LOD	286.0	109.0	80	6	Negative
CAT di glucuronide	2.83 (<LOD)	461.0	109.0	80	6	Negative
CAT sulfate	1.59 (<LOD)	189.0	109.0	80	6	Negative
CAT glucuronide-sulfate	1.38 (<LOD)	365.0	109.0	80	6	Negative
CAT di-sulfate	<LOD	269.0	109.0	80	6	Negative
<i>3,4-Dihydroxyphenylacetic acid metabolites</i>						
3,4-Dihydroxyphenylacetic acid (DHPAA)	1.80	166.8	123.2	70	5	Negative
DHPAA glucuronide	1.58	342.8	166.8	70	5	Negative
DHPAA di-glucuronide	1.04	518.8	166.8	70	5	Negative
DHPAA sulfate	1.14	246.8	166.8	70	5	Negative
DHPAA glucuronide-sulfate	0.74	422.8	166.8	70	5	Negative
DHPAA di-sulfate	1.07	326.8	166.8	70	5	Negative
<i>Hippuric acid metabolites</i>						
Hippuric acid (HA)	2.55	178.0	134.4	80	5	Negative
HA glucuronide	1.70 (<LOD)	354.0	178.0	80	5	Negative
HA di-glucuronide	0.59 (<LOD)	530.0	178.0	80	5	Negative
HA sulfate	1.78	258.0	178.0	80	5	Negative
HA glucuronide-sulfate	1.50	434.0	178.0	80	5	Negative
HA di-sulfate	<LOD	338.0	178.0	80	5	Negative
<i>Gallic acid metabolites</i>						
Gallic acid (GA)	0.71 (<LOD)	169.0	125.0	70	10	Negative
GA glucuronide	<LOD	345.0	169.0	70	10	Negative
GA di-glucuronide	<LOD	521.0	169.0	70	10	Negative
GA sulfate	<LOD	249.0	169.0	70	10	Negative
GA glucuronide-sulfate	<LOD	425.0	169.0	70	10	Negative
GA di-sulfate	<LOD	329.0	169.0	70	10	Negative
<i>Trans-ferulic acid metabolites</i>						
Trans-ferulic acid (TFA)	4.46	192.8	133.8	20	5	Negative
TFA glucuronide	4.25	368.8	192.8	20	5	Negative
TFA di-glucuronide	1.74 (<LOD)	544.8	192.8	20	5	Negative
TFA sulfate	3.56 (<LOD)	272.8	192.8	20	5	Negative
TFA glucuronide-sulfate	<LOD	448.8	192.8	20	5	Negative
TFA di-sulfate	1.32	352.8	192.8	20	5	Negative

<LOD, lower than the limit of detection.

Table 3. Qualitative analysis of anthocyanin and flavanone metabolites in plasma after the ingestion of maqui-citrus juices determined by UHLC-ESI-QqQ-MS/MS operated in multiple reaction monitoring, in negative and positive ionization modes, respectively (*Cont.*).


<i>2,4,6-Trihydrobenzaldehyd metabolites</i>						
2,4,6-Trihydrobenzaldehyd (THBA)	5.10	153.1	106.8	90	18	Negative
THBA glucuronide	5.08 (<LOD)	329.1	153.1	90	18	Negative
THBA di-glucuronide	<LOD	505.1	153.1	90	18	Negative
THBA sulfate	1.46	233.1	153.1	90	18	Negative
THBA glucuronide-sulfate	<LOD	409.1	153.1	90	18	Negative
THBA di-sulfate	<LOD	313.1	153.1	90	18	Negative
<i>Trans-isoferulic acid metabolites</i>						
Trans-isoferulic acid (TIFA)	1.46	193.7	134.7	70	5	Negative
TIFA glucuronide	<LOD	366.7	193.7	70	5	Negative
TIFA di-glucuronide	<LOD	545.7	193.7	70	5	Negative
TIFA sulfate	1.45 (<LOD)	273.7	193.7	70	5	Negative
TIFA glucuronide-sulfate	<LOD	449.7	193.7	70	5	Negative
TIFA di-sulfate	<LOD	353.7	193.7	70	5	Negative
<i>Vanillic acid metabolites</i>						
Vanillic acid (VA)	3.18	167.0	151.8	100	15	Negative
VA glucuronide	1.57 (<LOD)	343.0	167.0	100	15	Negative
VA di-glucuronide	1.01	519.0	167.0	100	15	Negative
VA sulfate	1.14	247.0	167.0	100	15	Negative
VA glucuronide-sulfate	0.93	423.0	167.0	100	15	Negative
VA di-sulfate	1.13 (<LOD)	327.0	167.0	100	15	Negative

<LOD, lower than the limit of detection.

495

496 FIGURES

497 Fig. 1.



NUTRITION, METABOLISM, AND CARDIOVASCULAR DISEASES

Sweetener influences plasma concentration of flavonoids in humans after an acute intake of a new (poly)phenol-rich beverage

HIGHLIGHTS

- Plasma concentration of bioavailable anthocyanins and flavanones was determined
- Sweetener were assessed on their capacity to influence the bioavailability of anthocyanins and flavanones
- The greatest bioavailability for these metabolites was provided by sucralose and stevia
- Sucralose and stevia are valuable alternatives to sucrose

NUTRITION, METABOLISM, AND CARDIOVASCULAR DISEASES

Sweetener influences plasma concentration of flavonoids in humans after an acute intake of a new (poly)phenol-rich beverage

CONFLICT OF INTEREST FORM

The authors declare neither financial nor other relationships that might lead to a conflict of interest.

Journal Pre-proof